Mogon Pharmaceuticals

Mogon Pharmaceuticals is a pre-clinical stage biotechnology company focused on developing novel small molecule therapeutics for neurological and psychiatric disorders. The company's primary focus is on the development of neurosteroid-based compounds that modulate GABA-A receptors to treat conditions such as epilepsy and post-traumatic stress disorder. By leveraging expertise in medicinal chemistry and neuropharmacology, Mogon aims to create fast-acting treatments with improved safety profiles compared to existing benzodiazepines. Their lead research programs target refractory seizures and acute anxiety-related conditions.